Li Xiao-Wei, Liu Yin, Gao Ming-Dong, Xiao Jian-Yong, Gao Jing
Thoracic Clinical College, Tianjin Medical University Tianjin 300070, P. R. China.
Department of Cardiology, Tianjin Chest Hospital Tianjin 300222, P. R. China.
Am J Transl Res. 2022 Jun 15;14(6):4139-4145. eCollection 2022.
Stent thrombosis (ST)-related ST-segment elevation myocardial infarction (STEMI) has very high mortality and poor prognosis. With the extensive construction of the chest pain center in China, the question arises as to whether these special patients will benefit.
From January 2015 to February 2018, 316 patients with STEMI admitted to the coronary care unit (CCU) of Tianjin Chest Hospital after coronary stent implantation were enrolled in this retrospective study. All patients underwent coronary angiography. According to whether STEMI was due to ST, these patients were divided into either a ST group (n=247) or a non-ST group (n=69). The in-hospital mortality and major adverse cardiac events (MACEs), including all-cause mortality, re-ST, target vessel revascularization (TVR), and acute myocardial infarction (AMI) within the 1-year follow-up were compared between the two groups.
78% of cases of STEMI following coronary stent implantation were caused by ST. The in-hospital mortality of the ST group was 0.8% and that of the non-ST group was 1.4% (P>0.05). Forty-two cases had MACEs in the 1-year follow-up, with a higher incidence in the ST group compared to the non-ST group (15.4% vs. 5.8%, P=0.038). The Kaplan-Meier survival analysis showed a lower 1-year event free survival (EFS) in the ST group compared to the non-ST group (84.6% vs. 94.2%, P=0.035). Age over 80-years-old, hypertension, diabetes, hypercholesterolemia, and family history of coronary artery disease (CAD) were all independent risk factors for MACE.
ST is the leading cause of STEMI in patients following coronary stent implantation. There was no significant difference in mortality between the ST group and the non-ST group during hospitalization, with a worse prognosis in the ST group during the 1-year follow-up.
支架内血栓形成(ST)相关的ST段抬高型心肌梗死(STEMI)死亡率极高且预后较差。随着中国胸痛中心的广泛建设,这些特殊患者是否会从中受益成为问题。
2015年1月至2018年2月,本回顾性研究纳入了316例在天津医科大学总医院冠心病监护病房(CCU)接受冠状动脉支架植入术后发生STEMI的患者。所有患者均接受冠状动脉造影。根据STEMI是否由ST引起,将这些患者分为ST组(n = 247)和非ST组(n = 69)。比较两组患者的院内死亡率和主要不良心脏事件(MACE),包括全因死亡率、再发ST、靶血管血运重建(TVR)以及1年随访期内的急性心肌梗死(AMI)。
冠状动脉支架植入术后STEMI病例中78%由ST引起。ST组的院内死亡率为0.8%,非ST组为1.4%(P>0.05)。1年随访期内有42例发生MACE,ST组的发生率高于非ST组(15.4%对5.8%,P = 0.038)。Kaplan-Meier生存分析显示,ST组的1年无事件生存率低于非ST组(84.6%对94.2%,P = 0.035)。年龄超过80岁、高血压、糖尿病、高胆固醇血症以及冠状动脉疾病(CAD)家族史均为MACE的独立危险因素。
ST是冠状动脉支架植入术后患者发生STEMI的主要原因。ST组和非ST组在住院期间死亡率无显著差异,但ST组在1年随访期内预后较差。